The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolytics<SUBTITLE>The PCI-CLARITY Study</SUBTITLE>
Abstract
CONTEXT: The benefit of clopidogrel pretreatment before percutaneous coronary intervention (PCI) remains debated and its use has not been universally adopted. OBJECTIVE: To determine if clopidogrel pretreatment before PCI in patients with recent ST-segment elevation myocardial infarction (STEMI) is superior to clopidogrel treatment initiated at the time of PCI in preventing major adverse cardiovascular events. DESIGN, SETTING, AND PARTICIPANTS: The PCI-Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY) study was a prospectively planned analysis of the 1863 patients undergoing PCI after mandated angiography in CLARITY-Thrombolysis in Myocardial Infarction (TIMI) 28, a randomized, double-blind, placebo-controlled trial of clopidogrel in patients receiving fibrinolytics for STEMI. Patients were enrolled at 319 sites in 23 countries from February 2003 through October 2004. INTERVENTIONS: Patients received aspirin and were randomized to receive either clopidogrel (300 mg loading dose, then 75 mg once daily) or placebo initiated with fibrinolysis and given until coronary angiography, which was performed 2 to 8 days after initiation of the study drug. For patients undergoing coronary artery stenting, it was recommended that open-label clopidogrel (including a loading dose) be administered after the diagnostic angiogram. MAIN OUTCOME MEASURES: The primary outcome was the incidence of the composite of cardiovascular death, recurrent MI, or stroke from PCI to 30 days after randomization. Secondary outcomes included MI or stroke before PCI and the aforementioned composite from randomization to 30 days. RESULTS: Pretreatment with clopidogrel significantly reduced the incidence of cardiovascular death, MI, or stroke following PCI (34 [3.6%] vs 58 [6.2%]; adjusted odds ratio [OR], 0.54 [95% CI, 0.35-0.85]; P = .008). Pretreatment with clopidogrel also reduced the incidence of MI or stroke prior to PCI (37 [4.0%] vs 58 [6.2%]; OR, 0.62 [95% CI, 0.40-0.95]; P = .03). Overall, pretreatment with clopidogrel resulted in a highly significant reduction in cardiovascular death, MI, or stroke from randomization through 30 days (70 [7.5%] vs 112 [12.0%]; adjusted OR, 0.59 [95% CI, 0.43-0.81]; P = .001; number needed to treat = 23). There was no significant excess in the rates of TIMI major or minor bleeding (18 [2.0%] vs 17 [1.9%]; P>.99). CONCLUSIONS: Clopidogrel pretreatment significantly reduces the incidence of cardiovascular death or ischemic complications both before and after PCI and without a significant increase in major or minor bleeding. These data add further support to the early use of clopidogrel in STEMI and the strategy of routine clopidogrel pretreatment in patients undergoing PCI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Steinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Mehta, S. R., Yusuf, S., & Peters, R. J. G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00559-7 · Cited by 2,578
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
Henn, V., Slupsky, J. R., Gräfe, M., Anagnostopoulos, I., Förster, R., Müller-Berghaus, G., & Kroczek, R. A. (1998) · Nature · doi:10.1038/35393 · Cited by 2,078
Schömig, A., Neumann, F.-J., Kastrati, A., Schühlen, H., Blasini, R., Hadamitzky, M., Walter, H., Zitzmann-Roth, E.-M., Richardt, G., Alt, E., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604253341702 · Cited by 2,028
Sabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., Claeys, M. J., Cools, F., Hill, K. A., Skene, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050522 · Cited by 1,924
Self-citationA Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting
Leon, M. B., Baim, D. S., Popma, J. J., Gordon, P. C., Cutlip, D. E., Ho, K. K. L., Giambartolomei, A., Diver, D. J., Lasorda, D. M., Williams, D. O., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812033392303 · Cited by 1,815
Platelet Activation in Unstable Coronary Disease
Fitzgerald, D. J., Roy, L., Catella, F., & FitzGerald, G. A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610163151602 · Cited by 1,141
Invited Commentary: Propensity Scores
Joffe, M. M., & Rosenbaum, P. R. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010011 · Cited by 1,048
The TIMI Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198903093201002 · Cited by 1,019
Fox, K. A. A., Mehta, S. R., Peters, R., Zhao, F., Lakkis, N., Gersh, B. J., & Yusuf, S. (2004) · Circulation · doi:10.1161/01.cir.0000140675.85342.1b · Cited by 835
Identification and Biological Activity of the Active Metabolite of Clopidogrel
Savi, P., Pereillo, J. M., Uzabiaga, M. F., Combalbert, J., Picard, C., Maffrand, J. P., Pascal, M., & Herbert, J. M. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614133 · Cited by 754
Bovill, E. G., Terrin, M. L., Stump, D. C., Berke, A. D., Frederick, M., Collen, D., Feit, F., Gore, J. M., Hillis, L. D., Lambrew, C. T., et al. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-4-256 · Cited by 479
Gersh, B. J., Stone, G. W., White, H. D., & Holmes, D. R. (2005) · JAMA · doi:10.1001/jama.293.8.979 · Cited by 439
MÜLLER, I., SEYFARTH, M., RÜDIGER, S., WOLF, B., POGATSA-MURRAY, G., SCHÖMIG, A., & GAWAZ, M. (2001) · Heart · doi:10.1136/heart.85.1.92 · Cited by 405
Steinhubl, S. R., Talley, J. D., Braden, G. A., Tcheng, J. E., Casterella, P. J., Moliterno, D. J., Navetta, F. I., Berger, P. B., Popma, J. J., Dangas, G., et al. (2001) · Circulation · doi:10.1161/01.cir.103.21.2572 · Cited by 355
STRATIFICATION BY A MULTIVARIATE CONFOUNDER SCORE
MIETTINEN, O. S. (1976) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112339 · Cited by 348
Platelet Function in Acute Myocardial Infarction Treated With Direct Angioplasty
Gawaz, M., Neumann, F.-J., Ott, I., Schiessler, A., & Schömig, A. (1996) · Circulation · doi:10.1161/01.cir.93.2.229 · Cited by 302
Cadroy, Y., Bossavy, J.-P., Thalamas, C., Sagnard, L., Sakariassen, K., & Boneu, B. (2000) · Circulation · doi:10.1161/01.cir.101.24.2823 · Cited by 266
ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction
(2004) · Circulation · doi:10.1161/circ.110.9.e82 · Cited by 215
Kastrati, A., von Beckerath, N., Joost, A., Pogatsa-Murray, G., Gorchakova, O., & Schömig, A. (2004) · Circulation · doi:10.1161/01.cir.0000137972.74120.12 · Cited by 196
Xiao, Z., & Théroux, P. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.10.071 · Cited by 177
Platelet Glycoprotein IIb/IIIa Inhibitors: Recognition of a Two-Edged Sword?
Quinn, M. J., Plow, E. F., & Topol, E. J. (2002) · Circulation · doi:10.1161/01.cir.0000019581.22812.b2 · Cited by 159
Chew, D. P., Bhatt, D. L., Robbins, M. A., Mukherjee, D., Roffi, M., Schneider, J. P., Topol, E. J., & Ellis, S. G. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01813-6 · Cited by 135
Gurbel, P. A., Cummings, C. C., Bell, C. R., Alford, A. B., Meister, A. F., & Serebruany, V. L. (2003) · American Heart Journal · doi:10.1067/mhj.2003.109 · Cited by 130
Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator.
Kerins, D. M., Roy, L., FitzGerald, G. A., & Fitzgerald, D. J. (1989) · Circulation · doi:10.1161/01.cir.80.6.1718 · Cited by 124
Rupprecht, H. J., Darius, H., Borkowski, U., Voigtländer, T., Nowak, B., Genth, S., & Meyer, J. (1998) · Circulation · doi:10.1161/01.cir.97.11.1046 · Cited by 122
Chan, A. W., Moliterno, D. J., Berger, P. B., Stone, G. W., DiBattiste, P. M., Yakubov, S., Sapp, S. K., Wolski, K., Bhatt, D. L., & Topol, E. J. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00944-6 · Cited by 116
Steinhubl, S. R., Ellis, S. G., Wolski, K., Lincoff, A. M., & Topol, E. J. (2001) · Circulation · doi:10.1161/01.cir.103.10.1403 · Cited by 112
Vivekananthan, D. P., Bhatt, D. L., Chew, D. P., Zidar, F. J., Chan, A. W., Moliterno, D. J., Ellis, S. G., & Topol, E. J. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.04.035 · Cited by 110
Management of Patients Undergoing Percutaneous Coronary Revascularization
Levine, G. N., Kern, M. J., Berger, P. B., Brown, D., Klein, L. W., Kereiakes, D. J., Sanborn, T. A., & Jacobs, A. K. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-2-200307150-00012 · Cited by 100
Helft, G., Osende, J. I., Worthley, S. G., Zaman, A., Rodriguez, O. J., Lev, E. I., Farkouh, M. E., Fuster, V., Badimon, J. J., & Chesebro, J. H. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.10.2316 · Cited by 93
Braunwald, E. (2003) · Circulation · doi:10.1161/01.cir.0000086952.14979.32 · Cited by 73
Lewis, B. S., Mehta, S. R., Fox, K. A. A., Halon, D. A., Zhao, F., Peters, R. J. G., Keltai, M., Budaj, A., & Yusuf, S. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.01.044 · Cited by 69
Platelets, Endothelial Cells, Inflammatory Chemokines, and Restenosis
Weyrich, A. S., Prescott, S. M., & Zimmerman, G. A. (2002) · Circulation · doi:10.1161/01.cir.0000033634.60453.22 · Cited by 66
Sabatine, M. S., McCabe, C. H., Gibson, C. M., & Cannon, C. P. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.11.006 · Cited by 56
Self-citationA Clinical Trial Comparing Three Antithrombotic-Drug Regimens After Coronary Artery Stenting
Leon, M. B., Baim, D. S., Popma, J. J., et al. (1999) · Survey of Anesthesiology · doi:10.1097/00132586-199908000-00006 · Cited by 56
Berger, P. B., & Steinhubl, S. R. (2002) · Circulation · doi:10.1161/01.cir.0000035924.70846.20 · Cited by 46
Assali, A. R., Salloum, J., Sdringola, S. M., Moustapha, A., Ghani, M., Hale, S., Schroth, G. W., Fujise, K., Anderson, H. V., Smalling, R. W., et al. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01897-5 · Cited by 34
Cited by
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Self-citationWriting Committee Members, Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31823ba622 · Cited by 3,289
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.007 · Cited by 2,164
Metadata
- Authors
- Sabatine, M. S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-09-14
- Volume
- 294
- Issue
- 10
- Pages
- 1224
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2104549091
- Cited by
- 716
- References
- 40
- FWCI
- 41.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.